BY MARKETWIRE
-
Zealand Pharma CEO: Metsera bidding war underscores obesity market priority
Zealand Pharma intends to develop a beneficial pipe and boost investor worth in collaboration with Roche
-
Lundbeck gets marketing approval for migraine drug Vyepti in Japan
Authorities in China and South Korea have actually additionally approved comparable advertising applications for authorization of Vyepti, the business’s significant developme…
-
Mikael Dolsten withdraws his candidacy for Novo Nordisk’s board
Current individual scenarios have actually led Mikael Dolsten to tip down as a participant and viewer.
-
Pfizer sells stake in vaccine partner BioNTech
The two companies have teamed up to develop a vaccine against COVID-19.
-
Lundbeck to acquire Irish biotech company for up to USD 2.25bn
The acquisition deal depends on $23.00 per share, and the complete deal might total up to USD 2.25 billion.
-
Novo Nordisk and Eli Lilly deny claims of collaboration with telehealth company
Both Novo Nordisk and Eli Lilly have actually rejected Mangoceuticals’ statement of a brand-new collaboration to market both business’ weight-loss medicines.
-
Bavarian Nordic CFO: Travel vaccine market share growing in Germany
Bavarian Nordic’s brand names acquire from favorable characteristics in Germany’s broadening market.
-
Convatec narrows forecast and signals what next year might offer
The clinical gadget business’s brand-new items supplied solid sales development, according to the chief executive officer.
-
Novo Nordisk likely to continue acquisition hunt after Metsera failure
This is according to an inner e-mail from chief executive officer Mike Doustdar, which Bloomberg has actually seen.
-
Novo Nordisk’s pricing deal with Trump sparks debate among analysts
JPMorgan checks out the arrangement favorably, as it can broaden accessibility to even more Medicare people, which might exceed the temporary unfavorable influence on sales develop…
